Diabetes is a complex metabolic syndrome that is characterized by prolonged high blood glucose levels and frequently associated with life-threatening complications 1,2 . Epidemiological studies have suggested that diabetes is also linked to an increased risk of cancer [3] [4] [5] . High glucose levels may be a prevailing factor that contributes to the link between diabetes and cancer, but little is known about the molecular basis of this link and how the high glucose state may drive genetic and/or epigenetic alterations that result in a cancer phenotype. Here we show that hyperglycaemic conditions have an adverse effect on the DNA 5-hydroxymethylome. We identify the tumour suppressor TET2 as a substrate of the AMPactivated kinase (AMPK), which phosphorylates TET2 at serine 99, thereby stabilizing the tumour suppressor. Increased glucose levels impede AMPK-mediated phosphorylation at serine 99, which results in the destabilization of TET2 followed by dysregulation of both 5-hydroxymethylcytosine (5hmC) and the tumour suppressive function of TET2 in vitro and in vivo. Treatment with the antidiabetic drug metformin protects AMPK-mediated phosphorylation of serine 99, thereby increasing TET2 stability and 5hmC levels. These findings define a novel 'phospho-switch' that regulates TET2 stability and a regulatory pathway that links glucose and AMPK to TET2 and 5hmC, which connects diabetes to cancer. Our data also unravel an epigenetic pathway by which metformin mediates tumour suppression. Thus, this study presents a new model for how a pernicious environment can directly reprogram the epigenome towards an oncogenic state, offering a potential strategy for cancer prevention and treatment.
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Diabetes is a complex metabolic syndrome that is characterized by prolonged high blood glucose levels and frequently associated with life-threatening complications 1, 2 . Epidemiological studies have suggested that diabetes is also linked to an increased risk of cancer [3] [4] [5] . High glucose levels may be a prevailing factor that contributes to the link between diabetes and cancer, but little is known about the molecular basis of this link and how the high glucose state may drive genetic and/or epigenetic alterations that result in a cancer phenotype. Here we show that hyperglycaemic conditions have an adverse effect on the DNA 5-hydroxymethylome. We identify the tumour suppressor TET2 as a substrate of the AMPactivated kinase (AMPK), which phosphorylates TET2 at serine 99, thereby stabilizing the tumour suppressor. Increased glucose levels impede AMPK-mediated phosphorylation at serine 99, which results in the destabilization of TET2 followed by dysregulation of both 5-hydroxymethylcytosine (5hmC) and the tumour suppressive function of TET2 in vitro and in vivo. Treatment with the antidiabetic drug metformin protects AMPK-mediated phosphorylation of serine 99, thereby increasing TET2 stability and 5hmC levels. These findings define a novel 'phospho-switch' that regulates TET2 stability and a regulatory pathway that links glucose and AMPK to TET2 and 5hmC, which connects diabetes to cancer. Our data also unravel an epigenetic pathway by which metformin mediates tumour suppression. Thus, this study presents a new model for how a pernicious environment can directly reprogram the epigenome towards an oncogenic state, offering a potential strategy for cancer prevention and treatment.
DNA methylation (5mC) and hydroxymethylation (5hmC) are epigenetic modifications that are frequently perturbed in cancer [6] [7] [8] . The conversion of 5mC to 5hmC occurs through an oxidative reaction catalysed by the ten-eleven translocation (TET) protein family of dioxygenases (TET1, TET2 and TET3) [9] [10] [11] . The reaction requires α-ketoglutarate, a metabolite that is influenced by the availability of glucose and glutamine 12, 13 . This led us to predict that a hyperglycaemic state would increase the levels of 5hmC in blood cells from patients with diabetes. To test this possibility, we examined global 5hmC in gDNA extracted from peripheral blood mononuclear cells (PBMC) collected from a cohort of healthy donors (haemoglobin A1c (HbA1c) 5.5 ± 0.26%) and patients with diabetes (HbA1c 10.7 ± 1.9%, Fig. 1a ). Unexpectedly, samples from patients showed a significant (P = 0.0017) decrease in 5hmC levels compared to the healthy donors (Fig. 1b, Extended Data Fig. 1a) , whereas 5mC levels remained the same (Fig. 1c) . The presence of diabetes in the patient group was the strongest predictor of low 5hmC levels, with HbA1c levels showing a significant (P < 0.05) inverse correlation with 5hmC (Extended Data Table 1a ).
To investigate this inverse correlation, we cultured several cell lines under normal glucose (1 g l
) and high glucose (4.5 g l ) conditions. A subset of these cell lines (PBMC, HUVEC and TF-1) exhibited significantly (P = 0.022 (PBMC), 0.046 (HUVEC), 0.047 (TF-1)) lower levels of 5hmC when subjected to high as opposed to normal glucose. The other cell lines (A375, A2058 and SK-MEL-5) did not show apparent changes in 5hmC levels between the two glucose conditions, as they have low baseline levels of 5hmC (Extended Data Fig. 1b) .
Loss of 5hmC is an epigenetic hallmark of cancer, in which diminished levels of TET2 expression have an important role 14, 15 . We hypothesized that the alterations in 5hmC in response to glucose were mediated through TET2, as TET1 and TET3 were barely detectable in these cells. Indeed, glucose-responsive cells (PBMC, HUVEC and TF-1) showed decreased TET2 in high glucose, whereas TET2 remained low and unaltered in the glucose-nonresponsive cells (A2058, A375 and SK-MEL-5) (Extended Data Fig. 1c) . To unravel the specific role of TET2 in this modulation, we used an A2058-TET2WT stable cell line, in which the expression of TET1 and TET3 is low and the expression of TET2 and 5hmC levels have been restored 15 (Extended Data Fig. 1d , e). High glucose reduced the level of TET2 protein in TET2WT cells, whereas the TET2 mRNA level remained unchanged (Extended Data  Fig. 1f, g ). Notably, the protein half-life of TET2 was substantially lower under high glucose than under normal glucose (Extended Data  Fig. 1h ). Unlike native A2058 cells (Extended Data Fig. 1b ), A2058-TET2WT cells showed a significant (P = 0.034) increase in 5hmC levels after 7 days of culture in normal glucose. This increase, however, could be reversed (within 24 h) by switching the culturing medium to high glucose (Fig. 1d, Extended Data Fig. 1i , j; see Supplementary Information for details). Such modulation was not observed in stable A2058 cell lines expressing mock control (mock), catalytically inactive full-length TET2 (TET2M), or catalytically active C-terminal TET2 (TET2CD) (Fig. 1e, Extended Data Fig. 1k ). These data suggest that functional, full-length TET2 is required to mediate the reversible changes in 5hmC in response to extracellular glucose availability.
To identify gene-specific 5hmC changes in response to glucose, we analysed genome-wide alterations in 5hmC in A2058-TET2WT cells using hydroxymethylated DNA immunoprecipitation coupled with deep sequencing (hMeDIP-seq) and methylated DNA immunoprecipitation coupled with deep sequencing (MeDIP-seq). These analyses showed that 5hmC was higher under normal glucose than high glucose, whereas there was no significant difference in 5mC (Fig. 1f, Extended  Data Fig. 2a) . We identified 30,217 differentially 5-hydroxymethylated regions (DhMRs), with more than 80% (about 24,537) of the regions being increased under normal glucose (Extended Data Fig. 2b, c) . The majority of this DhMR enrichment (65.4%) was associated with Letter reSeArCH gene regions, with 9.56% localizing to promoters and 55.84% to gene bodies (Fig. 1g, Extended Data Fig. 2d) . Notably, gene ontology and disease ontology analyses of these DhMR enriched genes showed strong associations with cancer and cancer-related pathways (Extended Data  Fig. 2e) .
We next used microarrays to compare transcriptomes of mock, A2058-TET2M and A2058-TET2WT cells cultured in normal or high glucose (Fig. 1h ). This analysis identified 585 genes that were differentially expressed in normal glucose versus high glucose when TET2 was present (A2058-TET2WT), but not in mock or A2058-TET2M cells (Fig. 1h , Extended Data Table 1b ). These glucose-modulated and TET2-dependent genes are involved in cell cycle regulation and are associated with various cancers (Extended Data Fig. 3a, b) . Among these genes, we found several tumour suppressor and tumour promoting genes that were downregulated and upregulated, respectively, under the high glucose condition, and validated a subset of these using quantitative PCR with reverse transcription (RT-qPCR) (Fig. 1i) . Furthermore, we found that 213 of the 585 genes (36.4%) contained increased DhMRs in normal glucose. Gene ontology and disease ontology analysis revealed that these 213 genes were also highly associated with cell cycle regulation and various types of cancers (Extended Data  Fig. 3c ). Of note, these genes consist of both upregulated and downregulated genes (Extended Data Fig. 3d ), suggesting that 5hmC has a complex role in gene regulation, as previously reported 16, 17 . AMPK is a key nutrient or energy sensor that is highly sensitive to glucose availability 18 . TET2 contains two putative AMPK motifs centred on serines 99 (S99) and 1205 (S1205) (Fig. 2a) . Furthermore, the activated form of AMPK (pAMPK172) was co-immunoprecipitated with TET2 (Fig. 2b) . To show that TET2 is a substrate of AMPK, we carried out an in vitro AMPK kinase assay (Fig. 2c, Extended Data  Fig. 4a) . By liquid chromatography with tandam mass spectrometry (LC-MS/MS) analysis, we detected robust phosphorylation of TET2, specifically at S99, by the active form of AMPK (Fig. 2d , Extended Data High-g Normal-g High-g* . Box plot: centre lines, median; limits, upper and lower quartiles; top and bottom whiskers, 10% and 90% percentiles; points, outliers. b, High-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) analysis of ratio of 5hmC to total C in randomly selected gDNA from 15 healthy donors and 18 patients. ****P = 7.44 × 10 −5 . c, HPLC-MS/MS analysis of ratio of 5mC to total C from the same samples as in b. d, Left, dot blot of 5hmC in DNA extracted from A2058-TET2WT cell line cultured in high glucose (high-g) or normal glucose (normal-g), or switched from normal to high glucose (high-g*). Right, quantification of dot blots. *P = 0.034 (high-g), P = 0.026 (high-g*). e, Dot blot comparison of 5hmC levels in A2058-TET2WT, mock (an A2058 cell line stably expressing empty vector), A2058-TET2M, and A2058-TET2CD cell lines cultured in high and normal glucose. f, Normalized hMeDIP-seq 5hmC tag density distribution across gene bodies in A2058-TET2WT cells cultured in high glucose (red) or normal glucose (blue). Each gene body was normalized relative to position percentage within the gene. g, hMeDIP-seq results of representative genes in which 5hmC is increased across the gene body in normal glucose. y-axis represents 5hmC density. h, Unguided clustering of genes that are differentially expressed when TET2 is present (in red frame) and not differentially expressed when TET2 is absent. Mut, A2058-TET2M. i, RT-qPCR validation of a subset of cancer-associated genes identified in h. Data represent three technical repeats in i and three biologically independent repeats in d, e. Two-sided Student's t-test, data shown as mean ± s.d., *P < 0.05, ****P < 0.0001. showed that TET2S99 is specifically phosphorylated in the presence of active AMPK. e, Immunoblot validation of TET2pS99 phosphorylation using a TET2pS99-specific antibody. f, Determination of TET2 phosphorylation at S99 via 32 P-autoradiograph (SLF is a naturally occurring mutant that probably disrupts the AMPK binding site). Data represent three biologically independent repeats in b, e, f. Fig. 4b ). There was little change to the other putative phosphorylation sites, including S1205. We next generated an antibody that specifically recognizes the phosphorylated form of TET2 S99 (Extended Data  Fig. 4c ). Immunoblotting confirmed the specificity of the antibody, as it gave a strong signal when used against AMPK-treated TET2WT, but not with untreated TET2WT or TET2 with a serine-to-alanine mutation at position 99 (TET2S99A) (Fig. 2e) . Using a 32 P radiolabelling kinase assay, we observed a marked decrease in γ-ATP incorporation in the TET2S99A mutant as well as in the S102_L103 >F (SLF) mutant (http://cancer.sanger.ac.uk/cosmic). By contrast, TET2WT and the S1205A mutant demonstrated comparably high levels of radioactivity (Fig. 2f, Extended Data Fig. 4d ). These findings reveal that TET2 is a substrate of AMPK and that S99 is the major phosphorylation site catalysed by AMPK.
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AMPK is known to be activated upon energy stress induced by glucose depletion 19, 20 . We hypothesized that glucose-mediated TET2 protein stability was modulated through phosphorylation of TET2S99 by AMPK. To test this hypothesis, we first compared TET2S99 phosphorylation levels in A2058-TET2WT cells cultured in normal glucose versus high glucose. Both western blot (P = 0.027) and HPLC-MS analysis (P = 0.030) revealed that the phosphorylation status of TET2S99 (TET2pS99) was significantly higher in normal as compared to high glucose (Fig. 3a, b, Extended Data Fig. 5a ). Consistent with the kinetics of 5hmC shown in Extended Data Fig. 1i , j, we observed steady increases in pAMPK, TET2pS99 and TET2 during days 0, 2 and 4 after switching from high to normal glucose (Extended Data  Fig. 5b ). These increases were confirmed in other cell lines as well as in PBMCs (Extended Data Fig. 5c) . Notably, pAMPK, TET2pS99 and total TET2 were significantly (P = 1.01 × 10 −6 (TET2), 0.0035 (TET2pS99), 5.26 × 10 −4 (pAMPK)) higher in PBMCs from healthy donors than in those from patients with diabetes (Fig. 3c, Extended Data Fig. 5d ). This is consistent with our observation that 5hmC is increased in the healthy group (Fig. 1a, b) . Collectively, these data demonstrate that TET2 is phosphorylated at S99 by AMPK, which is suppressed under hyperglycaemic conditions.
To investigate the pivotal role of AMPK-mediated phosphorylation in TET2 stability and 5hmC levels, we measured the half-life of TET2 and corresponding AMPK activity in cells that were initially cultured in normal glucose and were then switched to high glucose or kept in normal glucose. As indicated by pAMPK (pThr172), AMPK retained phosphorylation activity in cells that were continually cultured in normal glucose, whereas it was deactivated in cells switched to high glucose. Concomitantly, we observed that the half-life of TET2 protein was substantially reduced in cells that were switched to high glucose (Fig. 3d) . Next, we treated cells with AMPK activators (metformin or A769662) 21, 22 . As predicted, the activators elevated the levels of pAMPK, TET2pS99, total TET2 (Extended Data Fig. 6a, b) and 5hmC (Fig. 3e) . When cells cultured in high glucose were treated with metformin or A769662, the half-life of TET2 increased notably (Fig. 3f, Extended Data Fig. 6c, d) . Furthermore, metformin treatment also increased 5hmC in a subset of DhMRs previously identified to be increased under normal glucose (Extended Data  Fig. 6e ). To demonstrate that AMPK directly regulates TET2 protein stability, we used short hairpin RNAs (shRNAs) to specifically knockdown AMPKα2, an AMPKα isoform enriched in the nucleus 23 , in A2058 cells expressing TET2WT or TET2S99A, the non-phosphorylatable mutant. AMPKα2 shRNAs effectively depleted AMPKα2 and resulted in a marked decrease in TET2WT protein but not in the S99A mutant Letter reSeArCH (Fig. 3g) . These data suggest that AMPK and TET2S99 phosphorylation are important for protecting TET2 stability.
To identify the role of S99 phosphorylation, we generated another A2058 stable cell line expressing a phospho-mimic mutant, TET2S99D (Extended Data Fig. 7a, b ).When treated with cycloheximide (CHX), the TET2S99A mutant exhibited less stability than the TET2S99D mutant (Fig. 3h) . Consistent with greater protein stability, the TET2S99D cells had higher 5hmC than TET2S99A cells in high glucose (Fig. 3i) . After knocking down AMPK, we observed a marked drop in 5hmC levels in wild-type cells, with no such effect in the TET2S99A or S99D cells (Fig. 3i, Extended Data Fig. 7c) .
Previous studies have shown that the stability of TET2 protein is regulated by calpain family proteases 24 , and phosphorylation can protect proteins from calpain cleavage 25 . Thus, we hypothesized that phosphorylation of S99 protects TET2 from calpain-mediated degradation. Indeed, treatment with a calpain inhibitor strongly stabilized TET2S99A and increased the protein level 3.7-fold, whereas only marginal effects were seen with TET2WT and TET2S99D (Extended Data  Fig. 7d ). Together, these results indicate that TET2pS99 is a 'phosphoswitch' that is regulated by AMPK and is critical for the regulation of the stability of TET2 and levels of 5hmC.
To investigate how this AMPK-TET2 axis translates sustained high glucose exposure into a cancer-prone phenotype, we investigated the effects of TET2 and glucose levels on cell proliferation. A2058-TET2WT cells showed significantly (P = 5.68 × 10 −5 ) higher cell proliferation rates in high glucose than in normal glucose, whereas mock cells showed little effect (Extended Data Fig. 8a) . Notably, this TET2-dependent and glucose-influenced growth phenotype was validated in an independent model, TF-1 cells 26 (Extended Data Fig. 8b-d) . These data suggest that TET2 has an important role in glucose-modulated tumour cell growth.
There is growing evidence that metformin, a widely used antidiabetic drug, is also a potential anti-cancer agent 27, 28 . We investigated whether the effect of metformin on cell proliferation also involves the AMPK-TET2-5hmC axis. We treated A2058-TET2WT, A2058-TET2S99A and mock cells with metformin and detected a significant (P = 0.026) increase in 5hmC levels in TET2WT cells, but not in TET2S99A or mock cells (Extended Data Fig. 8e ). Using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) proliferation assays, we examined the growth of cells treated with metformin and observed that metformin significantly (P = 7.18 × 10
) reduced the proliferation of TET2WT cells, but had no effect on TET2S99A or mock cells (Extended Data  Fig. 8f) .
Next, we analysed the anchorage-independent growth of TET2WT, TET2S99A and mock cells. Restoring TET2 expression reduced anchorage-independent growth of A2058 cells. However, this suppression was compromised in A2058 cells expressing TET2S99A (Extended Data Fig. 8g, h, 0 mM) . This phenomenon could be recapitulated in an independent cell line, MDA-MB-231 (Extended Data Fig. 8i-l) . Notably, metformin further reduced colony growth in a dose-dependent manner, adding another layer of suppression to A2058-TET2WT cells. By contrast, the TET2S99A mutant and mock cells did not show significant growth inhibition upon metformin treatment (Extended Data Fig. 8g, h, 2-4 mM) . Collectively, these results demonstrate in vitro that metformin requires the AMPK-TET2-5hmC axis to execute its anti-tumour effects.
To validate our hypothesis in vivo, we first generated BALB/c nude mice xenografted with TET2WT or mock A2058 tumours under both diabetic and non-diabetic conditions, as outlined in Extended Data Fig. 9a, b . In support of the role of TET2 as a tumour suppressor, TET2WT tumours were significantly smaller than those of the mock control in both diabetic ( Fig. 4a, c ; P = 8.3 × 10 −4
) and non-diabetic mice ( Fig. 4b, d ; P = 5.2 × 10 −6 ). Notably, TET2WT tumours in diabetic mice were significantly larger than those in non-diabetic mice (Extended Data Fig. 9e, f ; P = 0.026 without metformin treatment, P = 0.0023 with metformin treatment). By contrast, there was little difference between mock tumours grown in diabetic or non-diabetic mice. These results are consistent with a mechanism in which a sustained diabetic or hyperglycaemic environment impairs TET2-5hmC-mediated tumour suppression.
Next, we investigated whether we could observe the anti-tumour effects of metformin, also operating through the AMPK-TET2-5hmC axis, in vivo. We found that metformin imposed an additional layer of suppression on TET2WT tumours in both diabetic and non-diabetic mice (Extended Data Fig. 9c, d ). By contrast, mock tumours showed little, if any, difference in size under the same treatments. Notably, when we depleted TET2 expression in A2058-TET2WT cells, the tumours behaved similarly to mock tumours and were no longer suppressed by metformin (Extended Data Fig. 9g, h ). We should note that metformin did not change blood glucose levels, consistent with a previous report 29 (Extended Data Table 1c ). Nevertheless, immunohistochemical (IHC) staining for pAMPK showed that metformin treatment effectively increased pAMPK in both TET2WT and mock tumours (Extended Data Fig. 10a, c) . The levels of 5hmC, however, were increased only in TET2WT tumours treated with metformin (Extended Data Fig. 10b, d ). These data demonstrate in vivo that the anti-tumour effect of metformin requires a functional TET2 protein and acts downstream of the influence of glucose upon the AMPK-TET2-5hmC axis.
In summary, we have shown that sustained hyperglycaemia destabilizes the tumour suppressor TET2 and deregulates levels of 5hmC. We describe an environment-to-epigenome signalling pathway, the glucose-AMPK-TET2-5hmC axis, which links the level of extracellular glucose to the dynamic regulation of 5hmC-and, ultimately, diabetes to cancer. We have identified AMPK-mediated TET2 phosphorylation at S99 as a molecular switch that controls a pivotal step in the glucose-AMPK-TET2-5hmC axis. Disabling this switch causes calpain-mediated degradation of TET2, resulting in a dysregulated hydroxymethylome and transcriptome. Notably, the anti-tumour effect of metformin requires a functional AMPK-TET2-5hmC axis. We propose that the glucose-AMPK-TET2-5hmC axis, which may work separately or in conjunction with other cellular pathways such as those involving mTOR 30 , is a signalling pathway by which cancer-promoting environmental cues are directly linked to (TET2 versus mock), *P = 0.048 (TET2 versus TET2 + Met). d, n = 4-5, ****P = 5.2 × 10 −6 (TET2 versus mock), 0.0046 (TET2 versus TET2 + Met). Two-sided Student's t-test, data shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, not significant.
the reprogramming of a cancer-favourable epigenome. This epigenetic regulation may have a direct effect on the efficacy of metformin in preventing cancer, thus providing novel avenues for future clinical investigation.
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Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0350-5. Fig. 2 | Genome-wide alterations in 5mC and 5hmC under normal glucose compared with high glucose. a, Normalized 5mC tag density distribution of A2058-TET2WT across gene bodies under high glucose (red) and normal glucose (blue). Each gene body was normalized relative to position percentage within the gene. In contrast to 5hmC (Fig. 1f) , the 5mC landscape of A2058-TET2WT cells showed marginal differences between high and normal glucose conditions. b, Total peak numbers for differentially 5-hydroxymethylated regions (DhMRs) when comparing normal glucose to high glucose. We identified 30,217 DhMRs in total, among which the majority (>80%, ~24,537) were increased in normal glucose, whereas <20% were decreased. c, hMeDIPqPCR validation of DhMRs in a group of cancer-related genes including CHEK1, CENPA, MCM7, CREB3L2, GABPB1 and COBLL1 in A2058-TET2WT cells under high or normal glucose conditions; n = 3 biologically independent repeats. d, Genome-wide distribution of increased DhMRs in annotated genomic regions in A2058-TET2WT cells under normal glucose compared to high glucose. The majority of the DhMRs (65.4%) localized to transcribed gene regions, with 9.56% in promoters and 55.84% in gene bodies. e, Gene ontology (GO, left) and disease ontology (DO, right) analysis of genes (n = 11,475) that had increased DhMRs in A2058-TET2WT cells under normal glucose compared to high glucose. These genes were enriched in pathways related to cancer. d, Left, CHX was used to measure the half-life of Flag-TET2 in A2058-TET2WT cells treated with (+) or without (−) A769662 (100 μM) in high glucose. Right, quantification of normalized Flag-TET2WT treated with CHX and with (+) or without (−) A769662. A769662 increased TET2 stability from 42% to 73% at 4 h after CHX treatment. Data in a-d are representative of three biologically independent repeats each. e, hMeDIPqPCR showed that metformin treatment increased DhMRs to similar levels as observed in normal glucose in the previously validated genes in Extended Data Fig. 2c . n = 3 biologically independent repeats, data shown as mean ± s.d. Fig. 9 | The mouse study paradigm and examination of the regulatory function of the tumour-suppressive glucose-AMPK-TET2 axis in vivo. a, Division of mice into eight groups. b, Outline of experimental procedure. In brief, nude mice were first induced to develop diabetes, and then transplanted with designated tumour cells. Tumour formation and sizes were documented continuously for three weeks, followed by histological and pathological examination. See more details in Supplementary Information. c, d , Growth curves of A2058-TET2WT and A2058 mock tumours in diabetic (c) and non-diabetic (d) nude mice, with and without metformin treatment. n = 5, P = 0.048 in c; n = 4-5, P = 0.0046 in d. e, f, Comparison between endpoint A2058-TET2WT and mock tumour sizes in diabetic and non-diabetic mice. Mice were treated either with (f) or without (e) metformin, n = 4-5. Tumours from diabetic TET2 groups were significantly larger than that from nondiabetic TET2 groups in both e and f. However, mock groups showed no difference between diabetic or non-diabetic conditions in either e or f. *P = 0.026 (bottom), ***P = 0.00043 (top) in e; **P = 0.0023 (bottom), ***P = 0.00013 (top) in f. g, Western blot showed successful TET2 knock down (A2058-TET2KD cells) in comparison with its TET2WT precursor. Data are representative of three biologically independent repeats. h, Growth curves of A2058-TET2WT and A2058-TET2KD tumours with and without metformin treatment, n = 4-5. The curve indicates that A2058-TET2KD tumours were no longer suppressed by metformin, and grew larger than A2058-TET2WT tumours; *P = 0.031. Two-sided Student's t-test, data shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < < 0.001, ****P < 0.0001; ns, not significant.
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Experimental design 1. Sample size
Describe how sample size was determined.
Animal sample sizes are determined by sample size calculator. Type 1 error is set at 0.05. Power is set at 80%.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
To ensure reproducibility, experiments were performed with at least 3 independent biological repeats. All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Nude mice were randomly divided into four groups used for animal study. To compare 5hmC levels in PBMCs from control and diabetic patient groups, gDNA samples were randomly selected from each group for HPLC-MS/MS analysis.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All of the immunostained sections were reviewed and scored independently by two pathologists in a blinded manner without knowledge of the clinicopathological information.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
